Aquestive Therapeutics, Inc. $AQST Shares Purchased by BNP Paribas Financial Markets

BNP Paribas Financial Markets increased its holdings in shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST) by 6,233.4% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 1,171,675 shares of the company’s stock after acquiring an additional 1,153,175 shares during the period. BNP Paribas Financial Markets owned approximately 0.96% of Aquestive Therapeutics worth $7,569,000 as of its most recent SEC filing.

Other institutional investors have also recently modified their holdings of the company. NewEdge Advisors LLC acquired a new stake in shares of Aquestive Therapeutics during the 3rd quarter valued at about $28,000. Modern Wealth Management LLC acquired a new stake in shares of Aquestive Therapeutics during the 2nd quarter valued at about $33,000. Kestra Private Wealth Services LLC acquired a new stake in shares of Aquestive Therapeutics in the third quarter valued at about $60,000. Lineweaver Wealth Advisors LLC purchased a new stake in shares of Aquestive Therapeutics during the fourth quarter worth about $65,000. Finally, Victory Capital Management Inc. increased its stake in shares of Aquestive Therapeutics by 17.0% during the third quarter. Victory Capital Management Inc. now owns 12,794 shares of the company’s stock worth $72,000 after purchasing an additional 1,862 shares in the last quarter. 32.45% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of analysts have recently commented on AQST shares. Wall Street Zen raised shares of Aquestive Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, May 16th. Oppenheimer started coverage on Aquestive Therapeutics in a report on Friday, April 24th. They issued an “outperform” rating and a $8.00 price objective on the stock. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Aquestive Therapeutics in a report on Monday, April 20th. Two analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Buy” and an average target price of $8.80.

Insider Transactions at Aquestive Therapeutics

In other news, CEO Daniel Barber sold 8,257 shares of the business’s stock in a transaction that occurred on Friday, May 15th. The stock was sold at an average price of $4.29, for a total transaction of $35,422.53. Following the transaction, the chief executive officer directly owned 660,574 shares in the company, valued at $2,833,862.46. The trade was a 1.23% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 6.81% of the company’s stock.

Aquestive Therapeutics Trading Up 2.0%

AQST stock opened at $3.99 on Wednesday. Aquestive Therapeutics, Inc. has a 12-month low of $2.93 and a 12-month high of $7.55. The stock has a market cap of $500.55 million, a price-to-earnings ratio of -6.54 and a beta of 1.46. The business’s 50-day moving average is $4.14 and its 200 day moving average is $4.52.

Aquestive Therapeutics (NASDAQ:AQST) last posted its quarterly earnings data on Wednesday, May 13th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.14) by $0.07. The firm had revenue of $14.45 million during the quarter, compared to analyst estimates of $10.90 million. As a group, equities analysts forecast that Aquestive Therapeutics, Inc. will post -0.41 EPS for the current fiscal year.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc is a specialty pharmaceutical company focused on the development and commercialization of novel drug delivery systems. Leveraging its proprietary PharmFilm® technology, Aquestive designs thin-film formulations that facilitate sublingual, buccal and oral delivery of small molecules, offering rapid onset of action and improved patient compliance compared with traditional dosage forms.

The company’s lead product, Libervant® (diazepam) Buccal Film, is approved by the U.S.